市场调查报告书
商品编码
1276428
医学仿生学全球市场规模、份额和行业趋势分析报告:按疾病类型、应用(伤口癒合、组织工程、药物输送等)、区域展望和预测,2023-2029 年Global Medical Biomimetics Market Size, Share & Industry Trends Analysis Report By Disease Type, By Application (Wound Healing, Tissue Engineering, Drug Delivery and Others), By Regional Outlook and Forecast, 2023 - 2029 |
医疗保健领域的仿生学市场规模预计到 2029 年将达到 577 亿美元,预测期内復合年增长率为 6.9%。
对于仿生学、仿生学或仿生学的应用和转化人类应用,阐明令人兴奋的自然系统的功能和结构之间的潜在机制和联繫是单一的,无论是作为个人还是群体、健康的最终用户/消费者或患者邀请需要治疗的患者进行类似的患者旅程。 仿生学是一个跨学科领域,它利用化学、工程学和生物学的原理来创造模拟生物过程的材料、机器或合成系统。
基于仿生学的设计有望应用于药物输送、再生医学和组织工程。 药学和医学领域的仿生学在对抗癌症等危及生命的疾病方面也显示出巨大潜力。 医学仿生学市场的快速扩张主要是由于政府增加了对仿生学研究的投资,以及医疗保健领域医学工程和纳米技术的整合和进步。
COVID-19 影响分析
随着隔离的放鬆、疫苗接种的好处和 COVID-19 病例的减少,企业正在恢復程序以满足对其产品的需求。 许多国家的检疫和大流行情况正在改善,并且有明显的复苏趋势。 一些从业者通过实践本地和国际指导来开始他们的服务。 此外,医疗保健领域仿生学销量的增加、仿生学产品的技术进步、政府为减轻疾病负担所做的努力、监管部门的批准等,都增加了预测期内仿生学在医疗保健领域的市场份额。 因此,预计这些发展将在预测期内稳定市场并引发增长。
市场增长因素
人口的永久老龄化将增加对仿生学的需求
老龄化社会是影响新兴国家的最重要问题之一。 此外,心脏病、外周动脉疾病和静脉血栓栓塞等慢性病在老年人中的流行预计会增加医疗保健领域对仿生学的需求和采用。 根据美国疾病控制和预防中心的一项研究,到 2020 年,近 27% 的男性和超过 21% 的女性将患有外周血管疾病,超过 19.1% 的 55 至 65 岁人群将受到影响。 与人口老龄化相关的疾病患病率不断上升,以及仿生学在患者护理中的使用越来越多,这将推动市场增长。
纳米技术的市场开发支持市场增长
在预测期内,纳米技术创新推动药物输送系统的进步预计将对医学仿生学的发展产生积极影响。 纳米材料对生物医学应用具有吸引力,并基于其生物相容性、物理和化学特性在仿生医学中显示出巨大潜力。 仿生功能化纳米技术的发展使得利用源自细胞膜的成分对纳米材料进行功能化和改性成为可能,从而使仿生纳米材料具有更高的稳定性、生物相容性、特异性和靶向性。 因此,将仿生纳米材料用于非侵入性疾病诊断可能会在预测期内推动市场增长。
市场製约因素
与医学仿生学相关的高成本
仿生技术的开发需要復杂的製造程序,这会导致高昂的开发和製造成本。 这可以降低价格和可用性,使患者更难获得。 此外,细胞和基因疗法非常昂贵,因为製造传统药物和生物药物所需的化学物质比细胞和病毒载体更难处理。 因此,对于典型的生物製药,接受该药物治疗的患者数量将增加一倍,达到数千,甚至数百万。 因此,预计与医疗保健中的仿生学相关的高成本将阻碍预期期间的市场增长。
疾病类型的前景
医疗仿生学市场按疾病类型分为眼科、心血管科、骨科、牙科等。 2022 年,心血管领域在医疗保健领域的仿生学市场实现了大幅增长。 这是因为心血管疾病是全世界死亡的主要原因,每年有 1790 万人死亡。 每年有超过 210 万人植入 CVD 植入物以延长寿命。 作为一个额外的好处,在预测期内,该细分市场将受益于引入技术先进的产品和政府资金所带来的有利机会,这将增加仿生学在医疗保健中的使用,从而增加该细分市场的增长可能会加速。
使用展望
医疗仿生学市场按应用细分为伤口癒合、组织工程、药物输送等。 到 2022 年,伤口癒合部分将占医疗保健仿生学市场的最大收入份额。 这是由于手术病例的增加和慢性病发病率的上升,增加了对促进伤口癒合和伤口护理的产品的需求。 教育材料和仿生学的进步使得将纤维化伤口癒合转移到再生过程变得越来越有利。
区域展望
按地区划分,对北美、欧洲、亚太地区和拉美地区的医疗保健仿生学市场进行了分析。 到 2022 年,北美地区将在仿生学市场中产生最高的收入份额。 这是由于需要牙科仿生产品的牙科疾病增加,政府对仿生产品研究的支持力度加大,以及发达国家资本收入的显着增加。 此外,已经存在并努力降低支出水平的先进报销机制也有助于扩大市场。 因此,这些因素正在推动北美地区医疗仿生学市场的增长。
The Global Medical Biomimetics Market size is expected to reach $57.7 billion by 2029, rising at a market growth of 6.9% CAGR during the forecast period.
A medical product category, medical biomimetics, was created by taking design cues from natural components. Problems relating to cardiac diseases, orthopedic diseases, ocular diseases, and dental diseases are resolved using medical biomimetics. Drug delivery and tissue regeneration are two medical applications of biomimicry.
In order to use natural systems and organisms as the basis for new scientific, technical, and technological solutions suitable for interventional use in dentistry and medicine, including tissue bio-engineering, biomimicry is a fusion of approaches needing the detection, perception, observation, identification, and close study of these entities.
A similar journey invites elucidating the underlying mechanisms and connections between the function and structure of the stimulating natural system(s) for applied and translational biomimetics, biomimicry, or biomimetics to humans, whether as single individuals or in groups and when healthy end-users/consumers or patients in need of therapies. Biomimetics is a multidisciplinary field that utilizes principles from chemistry, engineering, and biology to create materials, machines, or synthetic systems that mimic biological processes.
Biomimetics-based designs have potential applications in drug delivery, regenerative medicine, and tissue engineering. In addition, utilizing biomimetics in the field of pharmaceutics and medicine shows great potential for addressing life-threatening illnesses such as cancer. The rapid expansion of the medical biomimetics market is primarily fueled by heightened government investment in biomimetics research, as well as the integration and advancements of medical engineering and nanotechnology in the healthcare sector.
COVID-19 Impact Analysis
Companies have restarted their procedures to fulfill the demand for products, as a result of the easing of lockdowns, the advantages of vaccinations, and a drop in COVID-19 cases. Quarantine and the pandemic scenario are getting better and clearly on the mend in many nations. Several practitioners have launched their services by putting local and international guidance into practice. Additionally, the market share for medical biomimetics increased during the forecast period due to increased sales of medical biomimetics, technological advancements in biomimetic products, government initiatives to lessen the burden of disease, and regulatory approval. Therefore, it is anticipated that these trends will stabilize the market and cause it to grow over the course of the forecast period.
Market Growth Factors
The constant aging of the population raises the demand for biomimetics
The growing older population is one of the most important concerns impacting emerging nations globally. It is also projected that the prevalence of chronic conditions in the elderly, such as heart disease, peripheral artery disease, and venous thromboembolism, will increase demand for and adoption of medical biomimetics. According to research by the Centers for Disease Control and Prevention, nearly 27% of men and more than 21% of women will have peripheral vascular disease in 2020, affecting more than 19.1% of people aged 55 to 65. As a result of expanding uses of biomimetics in patient care joined with the increasing number of diseases due to the aging population will aid in the market growth.
Growing nanotechnology development to support the market growth
The advancements in drug delivery systems brought about by nanotechnology innovations will positively affect the growth of medical biomimetics during the forecast period. Nanomaterials are appealing for biomedical applications and show tremendous potential in biomimicry medicine based on their biocompatibility, physical and chemical properties. The development of biomimetic functionalized nanotechnology has allowed for the functionalization and modification of nanomaterials by components obtained from cell membranes, resulting in biomimetic nanomaterials with improved stability, biocompatibility, specificity, and targeting. Thus, using biomimetic nanomaterials for non-invasive disease diagnosis can aid the market growth during the projected period.
Market Restraining Factors
High cost associated with medical biomimetics
The complicated manufacturing procedures needed to create biomimetic technology might make them expensive to develop and produce. This may reduce its accessibility to patients by lowering its pricing and availability. In addition, because it is much more difficult to work with the chemicals needed to make traditional pharmaceuticals and even biopharmaceuticals than working with cells or viral vectors, cell and gene therapies have become much more expensive. As a result, the number of patients who will receive the drug is multiplied by thousands or millions for typical biopharmaceuticals. Thus, the high cost associated with medical biomimetics is anticipated to hamper the market growth during the anticipated period.
Disease Type Outlook
Based on disease type, the medical biomimetics market is characterized into ophthalmology, cardiovascular, orthopedic, dental, and others. The cardiovascular segment procured a considerable growth rate in the medical biomimetics market in 2022. This is because, with 17.9 million deaths annually, CVD is the leading cause of death globally. Every year, more than 2.1 million people have CVD implants to prolong their lives. Additionally, during the forecast period, the segment will benefit from lucrative opportunities brought on by the introduction of technologically advanced products and government funding, which will increase the utilization of medical biomimetics and thereby surge the segment's growth.
Application Outlook
On the basis of application, the medical biomimetics market is classified into wound healing, tissue engineering, drug delivery, and others. The wound healing segment witnessed the largest revenue share in the medical biomimetics market in 2022. This is owing to a growing number of surgical cases and the rise in the incidence of chronic diseases, increasing the demand for products promoting wound healing and wound care. It is becoming increasingly advantageous to reroute fibrotic wound healing toward a regeneration process by advancing instructional materials and biomimetics.
Regional Outlook
Region wise, the medical biomimetics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generate the highest revenue share in the medical biomimetics market in 2022. This is due to increased dental disorders that necessitate dental biomimetics goods, increased government support for biomimetics product research, and a considerable increase in capital income in industrialized countries. In addition, the sophisticated reimbursement mechanism that already exists and strives to lower expenditure levels also contributes to the market's expansion. As a result, these elements fuel the medical biomimetics market growth in the North America region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zimmer Biomet Holdings, Inc., BioHorizons, Inc. (Henry Schein, Inc.), SynTouch Inc., CorNeat Vision Ltd., Osteopore International Pte Ltd, Curasan, Inc., Otsuka Medical Devices Co., Ltd. (Otsuka Holdings Co. Ltd.), Swedish Biomimetics 3000 ApS, Keystone Dental Group and Blatchford Limited.
Strategies Deployed in Medical Biomimetics Market
Oct-2022: CorNeat has launched EverMatrix tissue integrating material technology. Evermatrix features a 100% synthetic biomimetic extracellular matrix that merges with human tissue for a lifetime. It also features a flexible and tough body structure that maintains its form when drenched.
Jul-2022: Curasan AG launched CERASORB CPC bone fillers.CERASORB CPC features phosphate and calcium salts dispersed in biocompatible oil made from plant extracts. The product is used mainly for minimally invasive applications. By introducing this product, curasan AG has strengthened its position in the market by countering the problems faced by medical personnel due to following a rigid protocol during the treatment of the wound.
Apr-2022: Keystone Dental Group has teamed up with Milestone Scientific for a channel partnership regarding Milestone's STA Single Tooth Anesthesia System. The collaboration aims at providing better patient care for Keystone's customers.
Sep-2021: Keystone Dental Inc. took over Osteon Medical. The acquisition strengthens Keystone's position in the dental market and provides sales opportunities for its synergistic and expanded implants. Furthermore, Keystone would be able to serve its customers in a better way owing to the combined portfolio of the company after the acquisition.
Mar-2021: CorNeat has partnered with LiveU, a remote solution production and video streaming company, for developing Remote Surgeon Virtual Presence (RSVP) Solution. The new solution would allow CorNeat to spread its clinical trials to more sites. RSVP also serves as a compliment for launching Corneat Kpro to train surgeons virtually across the globe.
Jan-2021: Osteopore International has teamed up with Maastricht University Medical Centre to develop a bone implant solution that averts leg amputation. This collaboration is directed at the adoption of 3D-printed bioresorbable implants across a wide clinical base.
Aug-2020: Blatchford Limited has unveiled ElanIC, a firm, and lightweight microprocessor-enabled hydraulic ankle. ElanIC features a lightweight and compact waterproof design that provides greater comfort to the user. Furthermore, the prosthetic features a standing support mode to improve the resistance when the user is stationary. The benefits of the prosthetic include reduced risk of trips, increased walking speed, improved ground clearance, and enhanced control.
Market Segments covered in the Report:
By Disease Type
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures